A5 Laboratories Inc. (AFLB.OB) is looking to give the medical community a shot in the arm when it comes to the treatment of some serious diseases. The company has recently submitted a provisional patent application to protect its technology for the production of interferon-based products. A5 Labs’ lead product, VI-1718, has potential broad-based applications for the treatment of certain types of cancer as well as multiple sclerosis and viral infections.
Dr. Richard Azani, President and CEO of A5 said, “The submission of this patent application is a very significant milestone in the development of our interferon-based products. I am very proud of our research team for their tireless work in completing the scientific and technological basis for this patent. We are now ready to advance the company’s plans towards production and commercialization of these products.”
A5 Labs is a contract research-based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.
A5 Laboratories, Inc. has entered into a contract with BioActif, Inc. for analytical services, which will include method development, raw materials and finished goods testing and stability studies.
Dr. Azani said this of the contract: �We are extremely pleased to have reached this agreement with such prestigious brand company such as BioActif. BioActif�s selection of our services is a terrific endorsement of our capabilities including complex analytical procedures and stability studies, and it is another significant step in establishing A5 Labs as a premium world class CRO and biotechnology company.�
BioCurex Inc. (OTCBB:BOCX) reported that the International Society of Oncology and Biomarkers Congress Scientific Committee has accepted BioCurex’s presentation on the RECAF blood test potential to monitor cancer recurrence and treatment. The meeting will be held Sept. 3-8, 2010 in Munich, Germany and is broadly attended by scientists, physicians and biotechnology companies involved in cancer diagnostics.
In addition, Dr. Ricardo Moro, the Chief Executive Officer of BioCurex, has been invited to co-chair a panel discussion on biomarker statistics and make a presentation on the statistical challenges in developing new cancer markers.
“We have previously shown that the RECAF cancer test can be used in a variety of ways including screening and diagnostics,” stated Dr. Moro. “In this presentation, our results indicate that the RECAF test could also be used for predicting outcome or monitoring treatment for cancer recurrence. We show that this test has a high sensitivity and specificity in early stages of at least two of the most common types of cancers, prostate and breast, as well as the less frequent ovarian cancer. This strongly suggests that a RECAF positive test might precede the clinical expression of a recurrence and therefore allow the oncologist to detect recurrence and treat patients earlier.”
The European Group on Tumor Markers Recommendations (2005) state that markers for breast cancer should be determined every 2�4 months (according to the risk of recurrence) during the initial 5 years after diagnosis, then every 6 months during the next 3 years and at yearly intervals thereafter(1). That represents 15-30 tests per cancer patient during the first 5 years following diagnosis and 2 additional tests per year thereafter. This highlights the importance of an inexpensive, reliable cancer marker test and monitoring tool which BioCurex believes could be fulfilled by its RECAF blood test.
Dr. Moro added, “I am also flattered by the congress organizers’ invitation to co-chair a panel of the statistical process of discovering and validating new cancer markers. The concepts I will present have been used at BioCurex in our research and development program relating to our RECAF cancer tests.”
Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, will hold an investor conference call on Thursday, August 5, 2010 at 8:30 a.m. ET to discuss its second quarter 2010 results. Robert Chioini, Chairman and CEO, and Thomas Klema, CFO, will be hosting the call to review Rockwell’s results. Rockwell will be releasing the earnings results on the same date.
Rockwell Medical is a fully-integrated biopharmaceutical company offering innovative products and services initially targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia. An established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad, Rockwell provides products that are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Dialysis is a process that duplicates kidney function for patients who suffer from ESRD. There are approximately 400,000 ESRD patients in the United States, a prevalence growing at an annual rate of 4 percent, and approximately 2 million ESRD patients world-wide.
The Company is currently developing unique, proprietary renal drug therapies for iron treatment. These exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are designed to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of SFP for indications outside of hemodialysis.
No comments:
Post a Comment